Results 171 to 180 of about 320,078 (208)
Some of the next articles are maybe not open access.
Metabolism, 2005
To investigate some individual and genetic factors that may influence the response of low-density lipoprotein cholesterol (LDL-C) to pravastatin treatment, we recruited 440 subjects with hypercholesterolemia (mean age, 57 years; 43% men) from 21 primary health care centers-outpatient clinics into a prospective, multicentered intervention trial ...
Carlos, Lahoz +6 more
openaire +2 more sources
To investigate some individual and genetic factors that may influence the response of low-density lipoprotein cholesterol (LDL-C) to pravastatin treatment, we recruited 440 subjects with hypercholesterolemia (mean age, 57 years; 43% men) from 21 primary health care centers-outpatient clinics into a prospective, multicentered intervention trial ...
Carlos, Lahoz +6 more
openaire +2 more sources
Lipoprotein(a) Cholesterol Masquerading as Low-Density Lipoprotein Cholesterol
Journal of the American College of Cardiology, 2022Guillaume Paré +2 more
openaire +1 more source
Hormone and Metabolic Research, 2001
The atherogenicity of triglyceride-rich lipoprotein has been revealed. This study was performed to explore the clinical importance of triglyceride-rich lipoprotein by measuring its cholesterol content and comparing it with other lipoprotein fractions. Blood samples were obtained from 103 patients whose fasting plasma triglyceride concentration exceeded
M, Ai +6 more
openaire +2 more sources
The atherogenicity of triglyceride-rich lipoprotein has been revealed. This study was performed to explore the clinical importance of triglyceride-rich lipoprotein by measuring its cholesterol content and comparing it with other lipoprotein fractions. Blood samples were obtained from 103 patients whose fasting plasma triglyceride concentration exceeded
M, Ai +6 more
openaire +2 more sources
PCSK9 gene mutations and low-density lipoprotein cholesterol
Clinica Chimica Acta, 2014Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a newly-identified circulating protein in cholesterol metabolism in mammals, including humans, which has emerged as a new pharmacological target for hypocholesterolemia. It has been demonstrated that PCSK9 gene mutations are associated with hyper- or hypocholesterolemia.
Na-Qiong Wu, Jian-Jun Li
openaire +2 more sources
New therapies to reduce low-density lipoprotein cholesterol
Current Opinion in Cardiology, 2013Lipid-lowering is an intervention that reduces atherosclerosis and its complications. Statins currently form the standard of care but are not able to reduce low-density lipoprotein cholesterol (LDL-C) adequately in all patients - particularly those with familial hypercholesterolaemia and those with statin intolerance.Combination therapy with statins is
Anthony S, Wierzbicki +3 more
openaire +2 more sources
Calculation of Low-Density Lipoprotein Cholesterol
Archives of Internal Medicine, 1991To the Editor.— In their article, Leighton et al1used Systeme International (SI) units to report their results with the corresponding traditional units in brackets. However, the equation they included in their "Methods" section for the calculation of low-density lipoprotein cholesterol (LDL-C) can be applied only with the latter units.2The correct ...
openaire +1 more source
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007
A study to determine the utilization of calculated low density lipoprotein (c-LDL) cholesterol and measured low density lipoprotein (m-LDL) cholesterol was conducted. The test results of total cholesterol, triglyceride, HDL-cholesterol and m-LDL-cholesterol from the same individuals aged > or = 18 years who had the tests done at the Department of ...
Wanida, Wongtiraporn +6 more
openaire +1 more source
A study to determine the utilization of calculated low density lipoprotein (c-LDL) cholesterol and measured low density lipoprotein (m-LDL) cholesterol was conducted. The test results of total cholesterol, triglyceride, HDL-cholesterol and m-LDL-cholesterol from the same individuals aged > or = 18 years who had the tests done at the Department of ...
Wanida, Wongtiraporn +6 more
openaire +1 more source
The Journal of Applied Laboratory Medicine
Abstract Background Low-density lipoprotein cholesterol (LDL-C) is directly associated with coronary artery disease (CAD) risk. Subfractionation of LDL enables differentiation between large-buoyant LDL (>20.5 nm) and small-dense LDL (≤20.5 nm).
Nicholas E Larkey +4 more
openaire +2 more sources
Abstract Background Low-density lipoprotein cholesterol (LDL-C) is directly associated with coronary artery disease (CAD) risk. Subfractionation of LDL enables differentiation between large-buoyant LDL (>20.5 nm) and small-dense LDL (≤20.5 nm).
Nicholas E Larkey +4 more
openaire +2 more sources
Low-density lipoprotein cholesterol reduction by inhibition of PCSK9
Current Opinion in Lipidology, 2013To review the phase 1 and 2 trials with fully human monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 published in the last 18 months and provide comprehensive data that targeting proprotein convertase subtilisin/kexin type 9 very effectively reduces LDL-cholesterol (LDL-C).The trials studied a number of different populations ...
openaire +2 more sources
Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction
The American Journal of Cardiology, 2016Although many clinical trials and meta-analyses have demonstrated that lower serum low-density lipoprotein cholesterol (LDL-C) levels are associated with proportionately greater reductions in the risk of cardiovascular disease events, not all patients with hypercholesterolemia are able to attain risk-stratified LDL-C goals with statin monotherapy ...
openaire +2 more sources